Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bafna Pharmaceuticals Ltd
Operating Income
Bafna Pharmaceuticals Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
|
Operating Income
₹91m
|
CAGR 3-Years
65%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
₹63.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Income
₹53.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Income
₹135.6B
|
CAGR 3-Years
42%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Operating Income
₹59.6B
|
CAGR 3-Years
147%
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
₹33.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
Bafna Pharmaceuticals Ltd
Glance View
Bafna Pharmaceuticals Ltd. engages in the manufacture of drugs and medicines of life saving drugs. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2008-06-27. The firm is manufacturing over 336 licensed pharmaceutical formulations and has globally registered approximately 78 of its products. The firm caters to both domestic and international markets. The firm has two manufacturing facilities in Chennai. Its Madhavram facility manufactures finished solid oral and liquid oral dosage forms of Betalactam and Non-Betalactam and Cephalosporin products. The firm supplies its finished products to countries including Sri Lanka, Ghana, Ukraine, and Laos. The firm's subsidary include Bafna Lifestyles Remedies Limited.
See Also
What is Bafna Pharmaceuticals Ltd's Operating Income?
Operating Income
91m
INR
Based on the financial report for Dec 31, 2025, Bafna Pharmaceuticals Ltd's Operating Income amounts to 91m INR.
What is Bafna Pharmaceuticals Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
6%
Over the last year, the Operating Income growth was 82%. The average annual Operating Income growth rates for Bafna Pharmaceuticals Ltd have been 65% over the past three years , 6% over the past five years .
